Skip to main content
Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc. — Investor Relations & Filings

Ticker · LYRA ISIN · US55234L1052 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2021-05-28 Director's Dealing
Country US United States of America
Listing US LYRA

About Lyra Therapeutics, Inc.

https://lyratherapeutics.com/

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company that develops and commercializes innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). The company's product candidates are long-acting, anti-inflammatory sinonasal implants designed to deliver medication directly to sinonasal tissues. This approach aims to provide a new, long-lasting treatment option for patients with this debilitating inflammatory disease, targeting tissues that are not easily accessible with conventional therapeutic methods.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2021-05-28 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a $50 million common stock offering by Lyra Therapeutics, Inc. It details the terms of an at-the-market offering, the sale agreement with Jefferies LLC, and includes sections such as risk factors, use of proceeds, dividend policy, and plan of distribution. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, management discussion, or any other report type. It clearly relates to financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, supporting a high confidence level.
2021-05-25 English
Regulatory Filings 2021
Regulatory Filings
2021-05-21 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from Lyra Therapeutics, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It references a registration statement number and requests the SEC to declare it effective by a certain date and time. This is a procedural communication related to a securities registration filing, specifically concerning the timing of the effectiveness of a registration statement. It does not contain financial data, earnings, management discussion, or any report content. It is not a report itself but an announcement/request related to a regulatory filing. Given the nature and length (1644 characters), it is not a full report but a regulatory communication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-05-18 English
SC 13G/A
Major Shareholding Notification
2021-05-17 English
Regulatory Filings 2021
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify the document as any specific filing type. According to the fallback rule, when a document does not fit any specific category or lacks identifiable content, it should be classified as a Regulatory Filing (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable. Therefore, the best classification is RNS with moderate confidence due to lack of content clarity.
2021-05-17 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.